Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:04:30 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:NVCR - NOVOCURE LTD - https://www.novocure.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NVCR - Q0.110.00·11.280.110.14+0.050.51,850.317,97316,99210.338  10.37  9.9323.18  9.8217:53:12Jan 1215 min RT 2¢

Recent Trades - Last 10 of 16992
Time ETExPriceChangeVolume
17:53:12Q10.190.1015
17:11:12Q10.140.0519
17:11:12Q10.14010.050119
16:32:33Q10.08-0.0110
16:10:04Q10.140.051
16:10:04Q10.140.051
16:05:37Q10.120.031
16:04:55Q10.140.051
16:04:52Q10.140.051
16:04:42Q10.140.051

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-12 07:00U:NVCRNews ReleaseNovocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
2025-12-22 07:00U:NVCRNews ReleaseNovocure to Present at 44th Annual J.P. Morgan Healthcare Conference
2025-12-01 07:00U:NVCRNews ReleaseNovocure Appoints Company President Frank Leonard as Chief Executive Officer
2025-11-26 07:00U:NVCRNews ReleaseNovocure to Participate in 37th Annual Piper Sandler Healthcare Conference
2025-11-12 07:00U:NVCRNews ReleaseNovocure to Participate in 2025 Jefferies Global Healthcare Conference
2025-10-30 07:00U:NVCRNews ReleaseNovocure Reports Third Quarter 2025 Financial Results
2025-10-15 07:00U:NVCRNews ReleaseNovocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
2025-10-01 07:00U:NVCRNews ReleaseNovocure to Report Third Quarter 2025 Financial Results
2025-09-29 16:30U:NVCRNews ReleaseNovocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
2025-09-15 07:00U:NVCRNews ReleaseNovocure's Optune Lua(TM) Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
2025-08-28 07:00U:NVCRNews ReleaseNovocure Announces Upcoming Investor Events
2025-08-25 07:00U:NVCRNews ReleaseNovocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
2025-08-20 07:00U:NVCRNews ReleaseNovocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
2025-07-24 07:00U:NVCRNews ReleaseNovocure Reports Second Quarter 2025 Financial Results
2025-07-01 07:00U:NVCRNews ReleaseNovocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
2025-06-30 07:00U:NVCRNews ReleaseNovocure to Report Second Quarter 2025 Financial Results
2025-05-31 08:00U:NVCRNews ReleaseResults From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
2025-05-27 07:00U:NVCRNews ReleaseNovocure Announces Upcoming Investor Events
2025-04-24 07:00U:NVCRNews ReleaseNovocure Reports First Quarter 2025 Financial Results
2025-04-23 10:16U:NVCRNews ReleaseNovocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting